(Acetazolamide + dronabinol) is under clinical development by Incannex Healthcare and currently in Phase II for Obstructive Sleep Apnea. According to GlobalData, Phase II drugs for Obstructive Sleep Apnea have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Acetazolamide + dronabinol)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Acetazolamide + dronabinol) overview

Fixed dose combination of acetazolamide and dronabinol (IHL-42X) is under development for the treatment of mild to moderate obstructive sleep apnoea (OSA). The drug candidate is a novel formulation of a synthetic (-) -Trans-delta-9-tetrahydrocannabinol (THC) with a mineral supplement combination. It is administered as capsule through oral route. The drug candidate acts by targeting cannabinoid receptor types 1 and 2 (CB1 and CB2).

Incannex Healthcare overview

Incannex Healthcare, is a pharmaceutical company. The company offers the development and manufacturing of cannabinoid medicine and therapeutic products. Its product portfolio includes releafia, nutralesic, inflammex, and cannagesia. Incannex Healthcare products are used in the treatment of obstructive sleep apnea, traumatic brain injury, sepsis-associated acute respiratory distress syndrome, and temporomandibular joint dysfunction. It also provides clinical trials and research and development services. It operates in Australia and New Zealand. Incannex Healthcare is headquartered in Melbourne, Victoria, Australia.

For a complete picture of (Acetazolamide + dronabinol)’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.